EP1263778B1 - Peptides inhibiteurs de l'interaction lfa-1/icam-1 - Google Patents

Peptides inhibiteurs de l'interaction lfa-1/icam-1 Download PDF

Info

Publication number
EP1263778B1
EP1263778B1 EP01942364A EP01942364A EP1263778B1 EP 1263778 B1 EP1263778 B1 EP 1263778B1 EP 01942364 A EP01942364 A EP 01942364A EP 01942364 A EP01942364 A EP 01942364A EP 1263778 B1 EP1263778 B1 EP 1263778B1
Authority
EP
European Patent Office
Prior art keywords
seq
icam
composition
lfa
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
EP01942364A
Other languages
German (de)
English (en)
Other versions
EP1263778A1 (fr
Inventor
Richard S. Larson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LARSON, RICHARD S.
Original Assignee
Larson Richard S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/483,550 external-priority patent/US6649592B1/en
Application filed by Larson Richard S filed Critical Larson Richard S
Publication of EP1263778A1 publication Critical patent/EP1263778A1/fr
Application granted granted Critical
Publication of EP1263778B1 publication Critical patent/EP1263778B1/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links

Definitions

  • the present invention relates to the field of biologically active peptide containing compositions for use in the prevention and treatment of hematopoietic neoplastic diseases, particularly leukemia.
  • LFA-1 lymphocyte function associated antigen-1
  • integrin ⁇ heterodimer Carlos and Harlan, 1994; Springer, 1994; Larson and Springer, 1990; McEver, 1990; Picker and Butcher, 1992.
  • three other integrins restricted in expression to leukocytes share the same ⁇ subunit and have homologous ⁇ subunits (Mac-1, p150,95, and alpha d)
  • only LFA-1 is expressed on normal and leukemia T cells (Larson and Springer, 1990).
  • LFA-1 binds ICAM-1 (intracellular adhesion molecule), and although LFA-1 is constitutively expressed on all leukocytes, LFA-1 binding to ICAM-1 requires cellular activation.
  • ICAM-1 Activation, in part, results in conformational changes in LFA-1 that affect its avidity for ICAM-1.
  • ICAM-1 is constitutively avid and expressed on a wide array of cell types including leukocytes, endothelium, stromal cells, and fibroblasts.
  • a stromal cell derived soluble factor cooperates with LFA-1 on the surface of T lineage acute lymphoblastic leukemia (T-ALL) cells (Winter et al ., 1998).
  • T-ALL T lineage acute lymphoblastic leukemia
  • the LFA-1 on T-ALL cells results in bone marrow (BM) stromal cell binding via ICAM-1 that leads to enhanced leukemia cell survival.
  • BM bone marrow
  • LFA-1/ICAM-1 dependent interaction between circulating leukemia cells and endothelial cells lining blood vessels promotes extravasation of leukemia cells into tissue as seen in the life-threatening therapeutic complication of acute leukemia, retinoic acid syndrome (Brown et al ., 1999).
  • LFA-1/ICAM-1 dependent interaction between circulating leukemia cells and endothelial cells lining blood vessels promotes extravasation of leukemia cells into tissue as seen in the life-threatening therapeutic complication of acute leukemia, retinoic acid syndrome (Brown et al ., 1999).
  • the present inventor has shown, for example, that inhibition of LFA-1/ICAM-1 dependent stromal cell binding with mAbs decreases survival of T-ALL cell lines and T-ALL cells isolated from patients.
  • a representative sample from a patient with T-ALL showed that survival of T-ALL cells is augmented by BM stromal cells and that survival is inhibited by mAbs directed against LFA-1 (mAb TSI/22,5 ⁇ g/ml) or its ligand ICAM-1 (mAb 84H10, 10 ⁇ g/ml). This observation has been replicated for T-ALL cell lines Jurkat and Sup T I as well as a subset of patients with T-ALL.
  • small peptide inhibitors Another means to interfere with protein-protein interactions is through the use of small peptide inhibitors.
  • small peptide inhibitors to adhesion molecules structurally-related to LFA-1 have recently been approved for clinical use in coagulopathies (Ohman et al ., 1995; Adgey et al ., 1998; Leficovis and Topol, 1995).
  • Short linear peptides ( ⁇ 30 amino acids) have also been described that prevent or interfere with integrin dependent firm adhesion using sequences derived from integrin or their ligands.
  • these peptides have been derived from a number of integrin receptors: the ⁇ 2 and ⁇ 3 subunits of integrins, and the ⁇ iib subunit of ICAM-1, and VCAM-1 (Murayama et al ., 1996; Jacobsson and Frykberg, 1996; Zhang and Plow, 1996; Budnik et al ., 1996; Vanderslice et al, 1997; Suehiro et al ., 1996; Endemann et al ., 1996).
  • the clinical applicability of these linear peptides is limited.
  • IC 50 concentration at which aggregation is inhibited 50%
  • concentration at which aggregation is inhibited 50% concentration at which aggregation is inhibited 50%
  • linear peptides have short serum half-lives because of proteolysis. Therefore, prohibitively high concentrations of peptide would have to be administered in a clinical setting and a biologic effect would not necessarily occur.
  • compositions that include cyclic peptide inhibitors of binding interactions between the integrin, lymphocyte function associated antigen-1 (LFA-1) expressed on leukocytes, including leukemic T-cells, and intracellular adhesion molecule 1 (ICAM-1), expressed on a variety of cell types.
  • LFA-1 lymphocyte function associated antigen-1
  • IAM-1 intracellular adhesion molecule 1
  • phage display has been used to identify peptide sequences that bind ICAM-1 and block LFA-1/ICAM interaction. Phage that specifically bound ICAM-1 were identified by repeated selection from a cysteine-constrained heptapeptide phage display library. The peptide sequences expressed on ICAM-1 binding phage were determined by nucleotide sequencing. A consensus sequence, CLLRMRSIC (SEQ ID NO: ) was derived from the analysis of the most frequently occurring sequences.
  • Another aspect of the present disclosure is the application of an alanine screening technique to the consensus sequence, SEQ ID NO: 1.
  • An alanine was substituted at each position in the hepatapeptide LLRMRSI of the consensus sequence SEQ ID NO: 1, and each peptide was examined in for its ability to inhibit LFA-1/ICAM-1 mediated cell aggregation.
  • Loss of inhibitory function resulted from alanine substitution of the leucines in positions 2 (SEQ ID NO: 34) and 3 (SEQ ID NO: 35), methionine in position 5 (SEQ ID NO: 37), and arginine in position 6 (SEQ ID NO: 38) of SEQ ID NO: 1, indicating that these amino acids are important to the antagonistic activity of the peptide.
  • Substitution of the serine in position 7 (SEQ ID NO: 39) had no significant effect on the inhibitory activity of the peptide.
  • Substitution of the arginine in position 4 ( i . e ., SEQ ID NO: 36) of SEQ ID NO: 1 was not soluble in aqueous solution at 1 nm and was not tested.
  • a further aspect of the present invention is the use of conservative amino acid substitutions of the key amino acid residues identified by the alanine screen. Sequences that exhibit greater inhibition of LFA-1/ICAM-1 mediated cell inhibition as compared to SEQ ID NO: 1, include CILRMRSAC (SED ID NO: 43), CLIRMRSAC (SEQ ID NO: 44), CLLKMRSAC (SEQ ID NO 45), CLLRMKSAC (SEQ ID NO: 46), and CLLRMRSVC (SEQ ID NO: 48).
  • the present invention may be described, therefore, in certain aspects as a composition comprising a cyclic peptide inhibitor of LFA-1/ICAM-1 interaction, wherein the composition has the amino acid sequence, CLLRMRSIC (SEQ ID NO: 1) or CLLRMRSAC (SEQ ID NO: 40), or a conservative variant thereof.
  • Conservative variants are described elsewhere herein, and include the exchange of an amino acid for another of like charge, size, or hydrophobicity, and include, but are not limited to, CILRMRSAC (SEQ ID NO: 43), CLIRMRSAC (SED ID NO: 44), CLLKMRSAC (SEQ ID NO 45), CLLRMKSAC (SEQ ID NO: 46), or CLLRMRSVC (SEQ ID NO: 48).
  • the present disclosure would also include variants of SEQ ID NO: 1 in which the 3 rd and 4 th amino acids remain the same and other amino acids of the sequence are substituted and tested empirically for their ability to inhibit the LFA-1/ICAM-1 interaction.
  • the amino acid sequence is numbered in the conventional sense, in that the first amino acid on the N-terminus is cysteine, followed by 7 amino acids and then a carboxy terminal cysteine.
  • the two terminal cysteines may form a disulfide bonded cystine residue resulting in a cyclic peptide as is well known in the art.
  • the terminal cysteines may be linked by an amide peptide linkage, either directly or separated by one or more amino acids, leaving two free sulfhydryl groups.
  • a cyclic peptide of the invention may have the sequence of SEQ ID NO: 1, or it may be a derivative of that sequence in which the second amino acid is methionine (SEQ ID NO: 17), or in which the 5 th amino acid is proline (SEQ ID NO: 5), or in which the 6 th amino acid is asparagine (SEQ ID NO: 9), or in which the 7 th amino acid is leucine (SEQ ID NO: 3), or in which the 8 th amino acid is arginine (SEQ ID NO: 2), or any combination of these substitutions, or even conservative variants of any of these substitutions.
  • Another aspect of the present invention includes cyclic peptides inhibitors of LFA-1/ICAM-1 interaction comprising the heptapeptide sequences which include LLRMRSI (SEQ ID NO: 49), LLRMRSA (SEQ ID NO: 50), LIRMRSA (SEQ ID NO: 51), LLKMRSA (SEQ ID NO 52), LLRMKSA (SEQ ID NO: 53), ILRMRSA (SED ID NO: 54) or LLRMRSV (SEQ ID NO: 55).
  • Peptides that comprise the heptapeptide sequences of the present invention may be a peptide of 7, or 8, or 9, or 10, or 11, or 12, or 13, or 14, or 15 amino acids in length, wherein additional amino acids may be any L-series or any D-series amino acid.
  • the peptides or peptide mimetics of the invention exhibit an inhibition constant (IC 50 ) for the binding interaction of LFA-1/ICAM-1 of from about 10 ⁇ M to about 800 ⁇ M for cell aggregation or from about 10 to about 250 nM for monovalent ICAM-1 binding.
  • IC 50 is well known in the art, and means the half maximal inhibitory concentration, or concentration at which aggregation is inhibited by 50%.
  • compositions described herein may be formulated for pharmacological or therapeutic administration either to a mammal, or more preferably to a human.
  • the compositions may be contained in a pharmaceutically acceptable carrier.
  • the preferred mode of administration of a peptide active agent is by injection, either intravenous, intra-arterial, intramuscular or subcutaneous. Other routes of administration may also be possible and would be included within the scope of the present disclosure.
  • compositions may be administered parenterally or intraperitoneally.
  • Solutions of the active compounds as free base or pharmacologically acceptable salts can be prepared in water suitably mixed with a surfactant, such as hydroxypropylcellulose.
  • Dispersions can also be prepared in glycerol, liquid polyethylene glycols, and mixtures thereof and in oils. Under ordinary conditions of storage and use, these preparations contain a preservative to prevent the growth of microorganisms.
  • the pharmaceutical forms suitable for injectable use include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions.
  • the form must be sterile and must be suitably fluid. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms, such as bacteria and fungi.
  • the carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), suitable mixtures thereof, and vegetable oils.
  • the proper fluidity can be maintained, for example, by the use of a coating, such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants.
  • a coating such as lecithin
  • surfactants for example, sodium sulfate, sodium sulfate, sodium sulfate, sodium sulfate, sodium sulfate, sodium sulfate, sodium sulfate, sodium sorbic acid, thimerosal, and the like.
  • isotonic agents for example, sugars or sodium chloride.
  • Prolonged absorption of the injectable compositions can be brought about by the use in the compositions of agents delaying absorption, for example, aluminum monostearate and gelatin.
  • Sterile injectable solutions are prepared by incorporating the active compounds in the required amount in the appropriate solvent with various of the other ingredients enumerated above, as required, followed by filtered sterilization.
  • dispersions are prepared by incorporating the various sterilized active ingredients into a sterile vehicle which contains the basic dispersion medium and the required other ingredients from those enumerated above.
  • the preferred methods of preparation are vacuum-drying and freeze-drying techniques which yield a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.
  • pharmaceutically acceptable carrier includes any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents and the like.
  • the use of such media and agents for pharmaceutical active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active ingredient, its use in the therapeutic compositions is contemplated. Supplementary active ingredients can also be incorporated into the compositions.
  • a peptide can be formulated into a composition in a neutral or salt form.
  • Pharmaceutically acceptable salts include the acid addition salts (formed with the free amino groups) and which are formed with inorganic acids such as, for example, hydrochloric or phosphoric acids, or such organic acids as acetic, oxalic, tartaric, mandelic, and the like. Salts formed with the free carboxyl groups can also be derived from inorganic bases such as, for example, sodium, potassium, ammonium, calcium, or ferric hydroxides, and such organic bases as isopropylamine, trimethylamine, histidine, procaine and the like.
  • aqueous solutions For parenteral administration in an aqueous solution, for example, the solution should be suitably buffered if necessary and the liquid diluent first rendered isotonic with sufficient saline or glucose.
  • aqueous solutions are especially suitable for intravenous, intramuscular, subcutaneous and intraperitoneal administration.
  • sterile aqueous media which can be employed will be known to those of skill in the art in light of the present disclosure.
  • one dosage could be dissolved in 1 mL of isotonic NaCI solution and either added to 1000mL of hypodermoclysis fluid or injected at the proposed site of infusion, (see for example, "Remington's Pharmaceutical Sciences" 15th Edition, pages 1035-1038 and 1570-1580). Some variation in dosage will necessarily occur depending on the condition of the subject being treated. The person responsible for administration will, in any event, determine the appropriate dose for the individual subject.
  • compositions may be used in adjunct therapy in standard treatments for diseases such as hematopoietic neoplasms.
  • the present invention may be described therefore, in certain embodiments as the use of a composition comprising a cyclic peptide, wherein the peptide comprises a heptapeptide sequence including, but not limited to, LLRMRSI (SEQ ID NO: 49), LLRMRSA (SEQ ID NO: 50), LIRMRSA (SEQ ID NO: 51), LLKMRSA (SEQ ID NO: 52), LLRMKSA (SEQ ID NO: 53), ILRMRSA (SEQ ID NO: 54) or LLRMRSV (SEQ ID NO: 55) for the manufacture of a medicament for preventing retinoic acid syndrome in a subject receiving all- trans retinoic acid.
  • LLRMRSI SEQ ID NO: 49
  • LLRMRSA SEQ ID NO: 50
  • LIRMRSA SEQ ID NO: 51
  • LLKMRSA SEQ ID NO: 52
  • the cyclic peptide has the amino acid sequence CLLRMRSIC (SEQ ID NO: 1) or CLLRMRSAC (SEQ ID NO: 40), or a conservative variant thereof, such as CILRMRSAC (SEQ ID NO: 43), CLIRMRSAC (SEQ ID NO: 44), CLLKMRSAC (SEQ ID NO: 45), CLLRMKSAC (SEQ ID NO: 46), or CLLRMRSVC (SEQ ID NO: 48).
  • An embodiment of the invention may also be described as the use of a cyclic peptide inhibitor of the LFA-1/ICAM-1 interaction, and further wherein the amino acid sequence of the cyclic peptide inhibitor is not a fragment of the amino acid sequence of LFA-1 or ICAM-1 for the manufacture of a medicament inhibiting growth of leukemia cells by preventing an LFA-1/ICAM-1 interaction between the leukemia cells and support cells such as bone marrow stromal cells.
  • An embodiment of the invention is also a therapeutic package for dispensing to, or for use in dispensing to, a mammal or human being treated for a hematopoietic neoplastic disease, myocardial infarction, radiation injury, asthma, rheumatoid arthritis, or lymphoma metastasis, wherein the package contains in a unit dose, an amount of a cyclic peptide comprising a heptapeptide sequence including, but not limited to, LLRMRSI (SEQ ID NO: 49), LLRMRSA (SEQ ID NO: 50), LIRMRSA (SEQ ID NO: 51), LLKMRSA (SEQ ID NO: 52), LLRMKSA (SEQ ID NO: 53), ILRMRSA (SEQ ID NO: 54) or LLRMRSV (SEQ ID NO: 55), effective to inhibit an LFA-1/ICAM-1 interaction in a subject when administered periodically.
  • LLRMRSI SEQ ID NO: 49
  • LLRMRSA SEQ ID NO
  • the cyclic peptide has the amino acid sequence CLLRMRSIC (SEQ ID NO: 1) or CLLRMRSAC (SEQ ID NO: 40), or a conservative variant thereof, such as CILRMRSAC (SEQ ID NO: 43), CLIRMRSAC (SEQ ID NO: 44), CLLKMRSAC (SEQ ID NO: 45), CLLRMKSAC (SEQ ID NO: 46), or CLLRMRSVC (SEQ ID NO: 48).
  • a unit dose is from about 10 to about 500 ⁇ g/Kg, or is from about 50 to about 250 ⁇ g/Kg, or from about 120 to about 150 ⁇ g/Kg.
  • the unit dose may be an initial bolus dose which may be followed by a continuous infusion of about 5 to about 250 ⁇ g/Kg/min, or from about 40 to about 60 ⁇ g/Kg/min, or may be about 50 ⁇ g/Kg/min.
  • unit doses may be repeated daily, and administered multiple times per day. Dosage regimens are not limited to those exemplified, and the invention encompasses any dosage regimen that delivers an therapeutically effective dose.
  • An example of clinical administration of a peptidomimetic inhibiting an integrin functions is documented by Ohman et al . (1995).
  • An embodiment of the present disclosure is the use of LLRMRSI (SEQ ID NO: 49), LLRMRSA (SEQ ID NO: 50), LIRMRSA (SEQ ID NO: 51), LLKMRSA (SEQ ID NO: 52), LLRMKSA (SEQ ID NO: 53), ILRMRSA (SEQ ID NO: 54) or LLRMRSV (SEQ ID NO: 55) for the manufacture of a medicament for inhibiting emigration of leukocytes from blood into tissue in a subject.
  • LLRMRSI SEQ ID NO: 49
  • LLRMRSA SEQ ID NO: 50
  • LIRMRSA SEQ ID NO: 51
  • LLKMRSA SEQ ID NO: 52
  • LLRMKSA SEQ ID NO: 53
  • ILRMRSA SEQ ID NO: 54
  • LLRMRSV LLRMRSV
  • the cyclic peptide has the amino acid sequence, CLLRMRSIC (SEQ ID NO: 1) or CLLRMRSAC (SEQ ID NO: 40), or a conservative variant thereof, such as CILRMRSAC (SEQ ID NO: 43), CLIRMRSAC (SEQ ID NO: 44), CLLKMRSAC (SEQ ID NO: 45), CLLRMKSAC (SEQ ID NO: 46), or CLLRMRSVC (SEQ ID NO: 48).
  • the subject is susceptible to the development of or is suffering from a hematopoietic neoplastic disease, myocardial infarction, radiation injury, asthma, rheumatoid arthritis, or lymphoma metastasis.
  • a further embodiment of the invention is a method comprising a competitive binding assay for screening the ability of candidate compounds to bind to ICAM-1.
  • the method comprises assessing the displacement of candidate compounds by cyclic petide inhibitors of LFA-1/ICAM-1 binding interaction.
  • the cyclic peptide may comprise a heptapeptide sequence including, but not limited to, LLRMRSI (SEQ ID NO: 49), LLRMRSA (SEQ ID NO: 50), LIRMRSA (SEQ ID NO: 51), LLKMRSA (SEQ ID NO: 52), LLRMKSA (SEQ ID NO: 53), ILRMRSA (SEQ ID NO: 54) or LLRMRSV (SEQ ID NO: 55).
  • the cyclic peptide has the amino acid sequence, CLLRMRSIC (SEQ ID NO: 1) or CLLRMRSAC (SEQ ID NO: 40), or a conservative variant thereof, such as CILRMRSAC (SEQ ID NO: 43), CLIRMRSAC (SEQ ID NO: 44), CLLKMRSAC (SEQ ID NO; 45), CLLRMKSAC (SEQ ID NO: 46), or CLLRMRSVC (SEQ ID NO: 48).
  • composition of the present application may be useful in therapy relating to tissue allografts such as renal, heart and thryoid allografts, bone marrow transplants, diabetes, rheumatoid arthritis, psoriasis, T-cell mediated sensitization reactions such as contact sensitization, and other T-cell mediated disorders, wherein LLRMRSI (SEQ ID NO: 49), LLRMRSA (SEQ ID NO: 50), LIRMRSA (SEQ ID NO: 51), LLKMRSA (SEQ ID NO: 52), LLRMKSA (SEQ ID NO: 53), ILRMRSA (SEQ ID NO: 54) or LLRMRSV (SEQ ID NO: 55), is used for the manufacture of a medicament.
  • tissue allografts such as renal, heart and thryoid allografts, bone marrow transplants, diabetes, rheumatoid arthritis, psoriasis, T-cell mediated sensitization reactions such as contact sensit
  • the cyclic peptide has the amino acid sequence, CLLRMRSIC (SEQ ID NO: 1) or CLLRMRSAC (SEQ ID NO: 40), or a conservative variant thereof, such as CILRMRSAC (SEQ ID NO: 43), CLIRMRSAC (SEQ ID NO: 44), CLLKMRSAC (SEQ ID NO: 45), CLLRMKSAC (SEQ ID NO: 46), or CLLRMRSVC (SEQ ID NO: 48).
  • LFA-1 and ICAM-1 are molecular targets for use in the therapy of acute leukemia using two assays that recapitulate the molecular and cellular events leading to leukemia cell proliferation in the marrow and spread of leukemia cells to distant sites.
  • the first assay simulates the marrow microenvironment
  • T-ALL T lineage acute lymphoblastic leukemia
  • BM bone marrow
  • T-ALL cells isolated from patients will die in ex vivo culture, and BM stromal cells have been shown to support ex vivo survival of T-ALL cells.
  • mAbs to LFA-1 and ICAM-1 dramatically decrease T-ALL cell survival by inhibiting adherence to bone marrow stromal cells. This latter finding indicates that survival of T-ALL cells in the marrow microenvironment is dependent on proper LFA-1/ICAM-1 binding.
  • adjunct therapy that included inhibition of LFA-1/ICAM-1 ligation between leukemia cells and T-ALL cells may cause T-ALL cell death and improved patient outcome. This may have applicability to all T-cell leukemias.
  • the present inventor has also established a model and dissected the mechanism of a life-threatening therapeutic complication of acute promyelocytic leukemia (APL), retinoic acid syndrome.
  • All- trans retinoic acid (ATRA) promotes a complete remission in up to 80% of patients with APL.
  • retinoic acid syndrome occurs in up to 30% of patients and is caused by APL cells infiltrating organs after retinoic acid therapy.
  • a parallel plate flow chamber the interactions that occur in blood vessels between circulating leukemia cells and endothelial cells have been recapitulated under physiologic flow conditions (Brown et al ., 1999; Larson et al ., 1997).
  • LFA-1 activity on APL cells after retinoic acid treatment results in APL cell binding to and transmigration through endothelium, analogous to the organ infiltration seen in APL patients being treated with retinoic acid.
  • mAbs against LFA-1 and ICAM-1 completely inhibit the binding to and transmigration through endothelium.
  • inhibition of LFA-1/ICAM interaction in patients with APL being treated with retinoic acid may protect against the development of retinoic acid syndrome.
  • LFA-1/ICAM inhibition is also applicable to the use of alternatives to retinoic acid, such as 9-cis-retinoic acid or various synthetic retinoids, in APL treatment, to the extent that they cause retinoic acid syndrome.
  • Inhibition of the LFA-1 and ICAM-1 binding has potential therapeutic benefits relating to blocking allograft rejection allografts, including cardiac, renal and thryoid allografts (Isobe et al ., 1992; Stepkowsld et al ., 1994; Cosimi et al ., 1990; Nakakura et al ., 1993; Talento et al ., 1993), bone marrow transplants (Tibbetts et al ., 1999; Cavazzana-Calvo et al ., 1995) T-cell mediated sensitization reactions (Ma et al ., 1994; Cumberbatch et al ., 1992), diabetes (Hasegawa et al ., 1994) and rheumatoid arthritis (Davis et al ., 1995; Kavanaugh et al ., 1994).
  • compositions of the present invention may be used in treatment of the above conditions and more generally in any condition T-cell mediated condition wherein T-cells are activated via interaction of LFA-1 and ICAM-1.
  • compositions that inhibit the LFA-1/ICAM-1 interaction.
  • compositions including nine amino acid peptides in which the terminal amino acids are cysteines, thus allowing the peptide to exist in a heterodetic cyclic form by disulfide bond formation or in a homodetic form by amide peptide bond formation between the terminal amino acids.
  • Cyclizing small peptides through disulfide or amide bonds between the N- and C-terminus cysteines may circumvent problems of affinity and half-life.
  • Disulfide bonds connecting the amino and carboxy terminus decrease proteolysis and also increase the rigidity of the structure, which may yield higher affinity compounds.
  • Peptides cyclized by disulfide bonds have free amino- and carboxy-termini which still may be susceptible to proteolytic degradation, while peptides cyclized by formation of an amide bond between the N-terminal amine and C-terminal carboxyl, no longer contain free amino or carboxy termini. Cyclic peptides may have longer half-lives in serum (Picker and Butcher, 1992; Huang et al., 1997). Moreover, the side-effects from peptide therapy are minimal, since anaphylaxis and immune responses against the small peptide occur only rarely (Ohman et al ., 1995; Adgey, 1998).
  • cyclic peptides have been shown to be effective inhibitors in vivo of integrins involved in human and animal disease (Jackson et al ., 1997; Cuthbertson et al ., 1997; Leficovis and Topol, 1995; Goligorsky et al ., 1998; Ojima et al ., 1995; Noiri et al ., 1994).
  • peptides of the present invention including CLLRMRSIC (SEQ ID NO: 1), CLLRMRSAC (SEQ ID NO: 40), CILRMRSAC (SEQ ID NO: 43), CLIRMRSAC (SEQ ID NO: 44), CLLKMRSAC (SEQ ID NO: 45), CLLRMKSAC (SEQ ID NO: 46), and CLLRMRSVC (SEQ ID NO: 48), can be linked either by a C-N linkage or a disulfide linkage.
  • heterodetic linkages may include, but are not limited to formation via disulfide, alkylene or sulfide bridges.
  • Methods of synthesis of cyclic homodetic peptides and cyclic heterodetic peptides, including disulfide, sulfide and alkylene bridges, are well known in the art. Some methods are disclosed in U.S. Patent No. 5,643,872. Other examples of cyclization methods are discussed and disclosed in U.S. Patent No. 6,008,058.
  • Cyclic peptides can also be prepared by incorporation of a type II' ⁇ -turn dipeptide (Doyle et al ., 1996).
  • embodiments of the present invention include cyclic peptides comprising the heptapeptides represented by residues 2 through 8 of the exemplified cysteine-containing nonapeptides.
  • embodiments of the present invention include cyclic peptides comprising the heptapeptide sequences LLRMRSI (SEQ ID NO: 49), LLRMRSA (SEQ ID NO: 50), LIRMRSA (SEQ ID NO: 51), LLKMRSA (SEQ ID NO: 52), LLRMKSA (SEQ ID NO: 53), ILRMRSA (SEQ ID NO: 54) and LLRMRSV (SEQ ID NO: 55).
  • Peptides that comprise the heptapeptide sequences of the present invention may be a peptide of 7, or 8, or 9, or 10, or 11, or 12, or 13, or 14, or 15 amino acids in length, wherein additional amino acids may be any L-series or any D-series amino acid.
  • phage display has been used to identify peptide sequences that bind ICAM-1 and block LFA-1/ICAM interaction. Briefly a library of cysteine-constrained heptapeptides was purchased from New England Labs (Cambridge, MA) and screened for its ability to bind the LFA-1 ligand, ICAM-1. Human ICAM-1 has been previously isolated in functional form (Larson et al ., 1990), and a variation of this technique was used to obtain purified recombinant soluble ICAM-1 for use in phage display. Each phage in the library has the potential to display a unique cyclic heptapeptide fused to its gene III coat on its surface.
  • the linkage of the displayed random peptide with a phage surface protein forms the basis of the technique.
  • the library consists of approximately 2.8 x 10 11 random heptapeptide sequences expressed on phage, compared to 20 7 (20 possible amino acids in 7 different positions) or 1.28 x 10 9 possible heptapeptide sequences.
  • the phage were then screened for their ability to bind purified ICAM-1 by interaction with the displayed heptapeptide sequences.
  • the phage were then screened for their ability to bind purified ICAM-1 by panning, wherein a library of phage, each displaying a different peptide sequence is applied to a surface coated with ICAM-1. Unbound phage is washed away.
  • Bound phage is eluted using the anti-ICAM-1 mAb 84h410.
  • This mAb binds to amino acid residues on ICAM-1 that are similar to those to which LFA-1 binds (Staunton et al ., 1990). Elution with R6.5 allowed for isolation of phage expressing cyclic peptides that bind a region on ICAM-1 that is shared with LFA-1 binding.
  • phage were eluted with mAb for 1 hour so that the peptides with highest affinity and slower off-rates ( i . e ., peptides most likely to be potent in vivo inhibitors) would be included.
  • peptide sequences that block ICAM-1/LFA-1 interactions are identified.
  • Adherent phage were selected and amplified in ER2537 bacteria through four rounds of panning. The sequences of 12-18 phage in each round were determined. A working consensus peptide was determined after nucleotide sequencing of 18 phage in the fourth and final round (Table 1). Amino acids that were recurring but occurred at lower frequency and did not fit into the consensus sequence are also shown below. The recurring amino acids form the basis of derivative structures. The ability of each phage isolated after four rounds of panning to specifically bind ICAM-1 was also determined in an ELISA assay with serial dilutions of phage.
  • PEPTIDE SEQUENCES EXPRESSED ON PHAGE THAT BIND ICAM-1 Amino acid position 1 2 3 4 5 6 7 8 9 Consensus (SEQ ID NO: 1) C L L R M R S I C Recurring amino acids M P N L R
  • LFA-1 dependent cell aggregation has been previously studied using an aggregation assay with a variety of leukocyte subclasses and cell lines (Larson et al ., 1990; Wang et al ., 1988; Larson et al ., 1997).
  • JY cells were obtained form American Type Tissue Culture Collection and were maintained in RPMI 1640 supplemented with 10% FBS at 37°C in 5% CO 2 . Aggregation of cells was measured in a homotypic aggregation assay using ICAM-1 as a stimuli. JY cells were washed twice with serum free medium and resuspended at a concentration of 4 x 105 cells/ml.
  • a co-culture assay has been developed by the present inventor that quantifies ex vivo survival of T-ALL cells (Winter et al ., 1998). Using this assay, survival of T-ALL cell lines as well as T-ALL cells isolated from patients required LFA-1 binding to ICAM-1 on bone marrow (BM) derived stromal cells.
  • BM bone marrow
  • cryopreserved or fresh leukemic samples are seeded onto HS5 stromal cell monolayers in 24 well plates.
  • the stromal cell line HS5 has been previously shown to support complete hematopoiesis of normal precursor cells (Roecklein and Torak-Storb, 1995).
  • HS5 cells are ⁇ -irradiated with 2500 cGy, a dose that has been determined to prevent stromal cell proliferation over 168 hours.
  • Leukemia cells are harvested at 1 and 96 hours. The number of leukemic cells recovered is measured in a flow cytometer by techniques based on those known in the art (Manabe et al ., 1992; Manabe et al ., 1994). The leukemia cells are stained by direct immunofluorescence using a fluoroisothiocyanate (FITC) labeled mAb directed against a pan T-ALL antigen CD5 as described (Larson et al ., Leukocyte Typing, 1990; Larson and McCurley, 1995).
  • FITC fluoroisothiocyanate
  • a gate is set around the area of light scatter where the viable CD5 positive T-ALL cells are found at the beginning of the cultures. Then, the T-ALL cells with predetermined light scattering and CD5 presentation are enumerated by counting the number of events passing through the gate in a 60 second time period. In each analysis 5 x 10 5 fluorescent Immuno-Chek beads (Coulter, Hialeah, FL) are added to each sample. The number of beads that pass through the flow cytometer in 60 seconds is also counted, allowing the measured bead number to serve as an internal control for the volume that passes through the flow cytometer in 60 seconds.
  • Parallel plate flow chamber for measuring leukocyte-endothelial cell interaction under physiologic flow conditions in vivo .
  • An assay has been developed that provides an in vitro model of neutrophils or APL cells binding to activated endothelium.
  • the binding of APL cells using a parallel plate flow chamber recapitulates events that occur in retinoic acid syndrome (Larson et al ., 1997; Brown et al ., 1999).
  • a parallel plate flow chamber simulates the physiologic flow conditions in blood and adhesive interactions in post-capillary venules.
  • Post-capillary venules are the physiologically relevant locations of leukemia cell-endothelial cell interaction and extravasation.
  • a parallel plate flow chamber is used to examine the inhibitory effects of peptides on APL cell line binding and transmigration through endothelium under physiologic flow conditions.
  • Monolayers of endothelial cells are placed in the parallel plate flow chamber, and the leukemic cells are pumped through the chamber at physiologic flow rates.
  • the interaction between the flowing leukemia cells and the endothelium are videotaped microscopically, and the number of rolling, firmly adhered and transmigrated leukemia cells is quantified by computer-assisted image analysis.
  • the APL cell line NB-4 acquires the ability to firmly attach to activated endothelium via LFA-1/ICAM-1 interaction. Inhibition of LFA-1/ICAM-1 interaction prevents firm adherence to and transmigration through endothelium of the APL cell line under physiologic flow. This has been demonstrated with monoclonal antibodies against LFA-1 and ICAM-1, which prevent firm attachment to and transmigration through activated endothelium of APL cells in a parallel plate flow chamber (Larson et al ., 1997; Brown et al ., 1999).
  • Flowing ATRA-treated APL cell lines over activated endothelial cell monolayers in a parallel flow chamber determines the effectiveness of peptides to inhibit LFA-1 dependent firm adherence and subsequent transmigration under physiologic flow conditions.
  • ICAM-1 expressed on activated endothelial monolayers are incubated with cyclic peptides over a range of concentrations (10 -4 to 10 -8 M) and the IC 50 is determined.
  • neutrophils are isolated from heparin anticoagulated venous blood of healthy adult donors by centrifugation on Ficoll-Hypaque density gradients as described by Simon et al. (1992). Isolated neutrophils are suspended at a concentration of 10 7 /ml in Hanks' Balanced Salt Solution supplemented with 10 mmol/L HEPES, pH 7.4 and 0.2% human serum albumin (Armour Pharmaceutical, Kankakee, IL) and used within 2 hours of preparation. Neutrophils are kept on ice and resuspended in RPMi pre-warmed to 37°C immediately before use.
  • hybridomas were grown by the present inventor and mAbs were purified for blocking studies.
  • the following monoclonal antibodies have been isolated from hybridoma supernatants: mAbs against LFA-1 (TS2/4 and TSI/22) and ICAM-1 (RRI/1, R6.5 and 84H10) (Larson et al ., 1997).
  • candidate compounds may be peptide or non-peptide compounds. Binding to ICAM-1 is quantified by the ability to displace a peptide of the present invention, including the peptides CLLRMRSIC (SEQ ID NO: 1), CLLRMRSAC (SEQ ID NO: 40), CILRMRSAC (SEQ ID NO: 43), CLIRMRSAC (SEQ ID NO: 44), CLLKMRSAC (SEQ ID NO: 45), CLLRMKSAC (SEQ ID NO: 46), and CLLRMRSVC (SEQ ID NO: 48), from ICAM-1.
  • CLLRMRSIC SEQ ID NO: 1
  • CLLRMRSAC SEQ ID NO: 40
  • CILRMRSAC SEQ ID NO: 43
  • CLIRMRSAC SEQ ID NO: 44
  • CLLKMRSAC SEQ ID NO: 45
  • CLLRMKSAC SEQ ID NO: 46
  • CLLRMRSVC SEQ ID NO: 48
  • radiolabeled peptide can be synthesized using commercial available radiolabeled amino acids precursors. Peptides radiolabelled with H 3 , C 14 or S 35 can be quantified by routine liquid scintillation techniques. Alternatively, a fluorescent labeled peptide can be synthesized. For example, lysine can be inserted in a non-critical position and labeled with fluroescein isothiocyanate ("FITC"). In addition to FITC, the peptide may be labeled with any suitable flurophore. A carboxy fluroescein derivative of SEQ ID NO: 1 has been prepared.
  • the 5(6)-carboxy fluorescein derivative of the disulfide constrained cyclic form of SEQ ID NO: 40, as shown by FIG. 3, has been synthesized by Biopeptide (San Deiego, CA):
  • peptides cyclized with an amide peptide linkage have free sulfhydryl groups available for linkage to fluorescent compounds such as thiocyanates. Separation of bound from unbound peptide and quantitation of displaced peptide can be performed by routine techniques known to one of skill in the art. This embodiment of the invention is not limited by the method used to quantify the displaced peptide, and any suitable analytical technique may be used and be within the scope of the invention.
  • the consensus peptide (SEQ ID NO: 1) and the randomized sequence CLMIRMLRC (SEQ ID NO: 33), cyclizied in the disulfide-linked form, were synthesized by Biopeptide (San Diego, CA) and tested in a screening assay for the ability to inhibit aggregation of the cell line JY, which aggregates in an LFA-1/CAM-1 dependent manner. Aggregation measurements are relatively rapid and quantifiable. Furthermore, small volumes are used minimizing peptide consumption. Finally, cell aggregation in vitro depends on a multivalent LFA-1/ICAM-1 interaction.
  • a peptide that is identified as being able to block cell aggregation in vitro is, therefore, likely to have affinity and off-rate characteristics that would make it an effective in vivo inhibitor, since cell-cell interaction in vivo also involves multivalent LFA-1 /ICAM-1 interaction.
  • the consensus peptide sequence has an IC 50 of 500 ⁇ M (FIG. 1).
  • the consensus peptide sequence (SEQ ID NO: 1) identified by phage display and described in Example 1 has an IC 50 Of 800 ⁇ M for cell aggregation and 250 nM for monovalent ICAM binding.
  • Monovalent ICAM-1 binding is measured by standard ELISA techniques, wherein, for example, the inhibition of 84H10 binding to ICAM-1 is assayed.
  • preferred peptides would have IC 50 's of about 10 ⁇ M to 800 ⁇ M for cell aggregation and from about 10 to 250 nM for monovalent ICAM binding.
  • standard techniques of designing derivative structures may be used to produce candidates to be tested for enhanced inhibitory capacity. This strategy has been shown to be effective in developing in vivo peptide inhibitors to other adhesion molecules (Ohman et al ., 1995; Adgey, 1998).
  • heptapeptide sequences are proposed on the basis of the observed consensus sequence of different phage sequences that were discovered in the phage display studies described above. Two of the amino acid positions in the consensus sequence show greater than 80% identity among phage and therefore are fixed (positions 3 and 4 of Table 1). The other positions are altered using 1 of 2 possible amino acids as shown in Table 2. The amino acids employed in the altered positions are identical to the recurring amino acids identified by phage display, but are represented at too low a frequency to be incorporated in the consensus sequence peptide. Using these combinations, 32 cysteine restrained heptapeptides are available as candidate inhibitors.
  • Peptides are initially tested for their ability to block LFA-1/ICAM dependent aggregation of the cell line JY (Wang et al ., 1988; Larson et al ., 1997). Peptides are preferably tested over a range of concentrations (10 1 to 10 8 ⁇ M, for example) and the concentration leading to half maximal inhibition of aggregation (IC50) is determined for all the peptide sequences. Peptide Antagonists Identified by Phage Display No. Sequence No.
  • SEQ ID NO: 36 representing a substitution of the arginine in position 4 of SEQ ID NO: 1, was not soluble at 1 nm and could not be tested. Loss of inhibitory function resulted from alanine substitution of the leucines in positions 2 (SEQ ID NO: 34) and 3 (SEQ ID NO: 35), methionine in position 5 (SEQ ID NO: 37), and arginine in position 6 (SEQ ID NO: 38) of SEQ ID NO: 1, indicating that these amino acids are important to the antagonistic activity of the peptide. Substitution of the serine in position 7 (SEQ ID NO: 39) had no significant effect on the inhibitory activity of the peptide.
  • SEQ ID NO: 40 The important amino acids of SEQ ID NO: 40, as identified by the alanine substitutions, were substituted with amino acids of like charge, e . g ., as described by Dayoff et al ., Atlas of Protein Sequence and Structure; vol 5, Suppl. 3, pp3,45-362 (M.O. Dayoff, ed., Nat'l BioMed Research Fdn., Washington, D.C. 1979). Peptides cyclizied in the disulfide-linked form were synthesized by Biopeptide (San Diego, CA) and were examined for their ability to inhibit LFA-1/ICAM-1 mediated JY cell aggregation. The results are summarized in Table 4.
  • CILRMRSAC SED ID NO: 43
  • CLIRMRSAC SEQ ID NO: 44
  • CLLKMRSAC SEQ ID NO 45
  • CLLRMKSAC SEQ ID NO: 46
  • CLLRMRSVC SEQ ID NO; 48.
  • This type of derivative strategy has previously been shown to be successful at identifying higher affinity peptides (Ohman et al ., 1995; Adgey, 1998).
  • conservative varaints can also be screened for other desirable properties such as a longer serum-half life or desirable other pharmacokinetic of pharmacodymanic properties.
  • the cyclic peptide inhibitors having the amino acid sequences, CLLRMRSIC (SEQ ID NO: 1) and CLLRMKSAC (SEQ ID NO: 46) have been shown to block neutrophil-binding to endothelium under physiologic flow conditions in a parallel plate flow chamber.
  • the data is shown in Table 5.
  • SEQ ID NO: 46 exhibited greater inhibition of attachment of neutrophils to activated endothelium.
  • the peptides of the present invention bind to ICAM-1 and block cell-cell adhesion that is dependent on LFA-1 binding to its ligand, ICAM-1. In contrast to other peptide inhibitors, these compounds have no structural similarity to fragments or portions of LFA-1 or ICAM-1. These compound are, therefore, effective agents in the treatment of myocardial infarction, rheumatoid arthritis, asthma, and leukemia/lymphoma, and are contemplated to be especially effective in adjunct therapy of acute T-ALL and retinoic acid syndrome in APL.
  • peptide inhibitor may be useful in 80% of cases of T-ALL when incorporated as adjunct therapy.
  • Side effects related to use of a small peptide are contemplated to be minimal, since peptidomitnetics inhibiting other integrin functions, and now in clinical trial do not have significant side-effects (Ohman et al ., 1995; Adgey, 1998).
  • LFA-1 may be critical to an aspect of hematopoiesis that is as yet undefined.
  • Jacobsson and Frykberg "Phage display shot-gun cloning of ligand-binding domains of prokaryotic receptors approaches 100% correct clones," Biotechniques 20:1070, 1996.
  • Stepkowski et al "Blocking of heart allograft rejection by intercellular adhesion molecule- I antisense oilgonucelotides alone or in combination with other immunosuppressive modalities," J Immunol ., 144:4604, 1990.
  • Vanderslice et al . "A cyclic hexapeptide is a potent antagonist of alpha4 integrins," J Immunol , 158:1710, 1997.
  • LMP Epstein-Barr virus latent infection membrane

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Claims (25)

  1. Composition comprenant un inhibiteur peptidique cyclique de l'interaction LFA-1/ICAM-1, dans laquelle ledit inhibiteur peptidique cyclique possède 7 à 10 acides aminés et se compose d'une séquence d'acides aminés choisie dans le groupe formé par SEQ ID N° : 49, SEQ ID N° : 50, SEQ ID N° : 51, SEQ ID N° : 52, SEQ ID N° : 53, SEQ ID N° : 54 et SEQ ID N° : 55.
  2. Composition de la revendication 1, dans laquelle ladite composition est contenue dans un support pharmaceutiquement acceptable.
  3. Composition de la revendication 1, dans laquelle ledit inhibiteur peptidique cyclique de l'interaction LFA-1/ICAM-1 possède une séquence d'acides aminés choisie dans le groupe formé par SEQ ID N° : 1, SEQ ID N° : 40, SEQ ID N° : 43, SEQ ID N° : 44, SEQ ID N° : 45, SEQ ID N° : 46 et SEQ ID N° : 48.
  4. Composition de la revendication 1, dans laquelle ladite composition présente une CI50 de l'agrégation cellulaire facilitée par la liaison LFA-1/ICAM-1 comprise entre environ 10 µM et environ 850 µM.
  5. Composition de la revendication 1, dans laquelle ladite composition présente une CI50 de la liaison de ICAM-1 monovalente comprise entre environ 10 nM et environ 250 nM.
  6. Composition comprenant un inhibiteur peptidique cyclique de l'interaction LFA-1/ICAM-1, dans laquelle ledit inhibiteur peptidique cyclique possède une séquence d'acides aminés choisie dans le groupe formé par SEQ ID N° : 1, SEQ ID N° : 40, SEQ ID N° : 43, SEQ ID N° : 44, SEQ ID N° : 45, SEQ ID N° : 46 et SEQ ID N° : 48.
  7. Composition de la revendication 6, dans laquelle ladite composition est contenue dans un support pharmaceutiquement acceptable.
  8. Composition de la revendication 6, dans laquelle ladite composition présente une CI50 de l'agrégation cellulaire facilitée par la liaison LFA-1/ICAM-1 comprise entre environ 10 µM et environ 850 µM.
  9. Composition de la revendication 6, dans laquelle ladite composition présente une CI50 de la liaison de ICAM-1 monovalente comprise entre environ 10 nM et environ 250 nM.
  10. Utilisation d'une composition de l'une quelconque des revendications 1 à 9 pour la fabrication d'un médicament destiné à inhiber, chez un sujet, l'interaction entre LFA-1 exprimé sur un leucocyte et ICAM-1 exprimée sur une seconde cellule.
  11. Utilisation de la revendication 10, dans laquelle ladite seconde cellule est une cellule stromale de la moelle osseuse.
  12. Utilisation de la revendication 10, dans laquelle ladite seconde cellule est une cellule endothéliale.
  13. Utilisation d'une composition de l'une quelconque des revendications 1 à 9 pour la fabrication d'un médicament pour la prévention du syndrome de l'acide rétinoïque chez un sujet recevant de l'acide tout trans rétinoïque.
  14. Utilisation d'une composition de l'une quelconque des revendications 1 à 9 pour la fabrication d'un médicament destiné à inhiber l'expansion de cellules leucémiques en empêchant une interaction LFA-1/ICAM-1 entre lesdites cellules leucémiques et des cellules stromales de la moelle osseuse.
  15. Conditionnement thérapeutique pour l'administration à, ou à usage dans l'administration à, un mammifère en traitement pour une maladie néoplasique hématopoïétique, un infarctus du myocarde, une affection radio-induite, l'asthme, une arthrite rhumatoïde, ou une métastase de lymphome, dans lequel ledit conditionnement contient dans une dose unitaire, une quantité d'une composition de l'une quelconque des revendications 1 à 9.
  16. Conditionnement de la revendication 15, dans lequel ledit conditionnement est préparé pour l'administration intraveineuse.
  17. Conditionnement de la revendication 15, dans lequel ledit conditionnement comprend ladite dose unitaire sous forme d'une poudre sèche.
  18. Conditionnement de la revendication 15, dans lequel ladite dose unitaire administrera une dose comprise entre environ 10 µg/kg et environ 500 µg/kg.
  19. Conditionnement de la revendication 15, dans lequel ladite dose unitaire administrera une dose comprise entre environ 50 µg/kg et environ 250 µg/kg.
  20. Utilisation d'une composition de l'une quelconque des revendications 1 à 9 pour la fabrication d'un médicament pour l'inhibition de l'émigration de leucocytes depuis le sang vers les tissus chez un sujet.
  21. Utilisation de la revendication 20, dans laquelle ledit sujet est prédisposé à l'apparition, ou est atteint, d'une maladie néoplasique hématopoïétique, d'un infarctus du myocarde, d'une affection radio-induite, d'asthme, d'arthrite rhumatoïde, ou de métastase de lymphome.
  22. Procédé de dépistage d'un composé candidat pour la liaison à l'ICAM-1 comprenant :
    (a) la mise en contact de l'ICAM-1 avec un peptide possédant 7 à 10 acides aminés et se composant d'une séquence d'acides aminés choisie parmi le groupe formé par SEQ ID N° : 49, SEQ ID N° : 50, SEQ ID N° : 51, SEQ ID N° : 52, SEQ ID N° : 53, SEQ ID N° : 54 et SEQ ID N° : 55, de manière telle que ledit peptide soit lié à ladite ICAM-1 ;
    (b) la mise en contact de ladite ICAM-1 portant ledit peptide lié avec ledit composé candidat ;
    (c) la quantification du peptide déplacé.
  23. Procédé de la revendication 22, dans lequel ledit peptide cyclique possède une séquence d'acides aminés choisie parmi le groupe formé par SEQ ID N° : 1, SEQ ID N° : 40, SEQ ID N° : 43, SEQ ID N° : 44, SEQ ID N° : 45, SEQ ID N° : 46 et SEQ ID N° : 48.
  24. Procédé de la revendication 22, dans lequel ledit peptide est marqué à l'aide d'un isotope radioactif.
  25. Procédé de la revendication 22, dans lequel ledit peptide est marqué à l'aide d'un fluorophore.
EP01942364A 2000-01-14 2001-01-16 Peptides inhibiteurs de l'interaction lfa-1/icam-1 Expired - Lifetime EP1263778B1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US483550 1983-04-11
US760599 1991-09-16
US09/483,550 US6649592B1 (en) 2000-01-14 2000-01-14 Peptide inhibitors of LFA-1/ICAM-1 interaction
US09/760,599 US6630447B2 (en) 2000-01-14 2001-01-16 Peptide inhibitors of LFA-1/ICAM-1 interaction
PCT/US2001/001382 WO2001051508A1 (fr) 2000-01-14 2001-01-16 Peptides inhibiteurs de l'interaction lfa-1/icam-1

Publications (2)

Publication Number Publication Date
EP1263778A1 EP1263778A1 (fr) 2002-12-11
EP1263778B1 true EP1263778B1 (fr) 2005-04-27

Family

ID=27047693

Family Applications (1)

Application Number Title Priority Date Filing Date
EP01942364A Expired - Lifetime EP1263778B1 (fr) 2000-01-14 2001-01-16 Peptides inhibiteurs de l'interaction lfa-1/icam-1

Country Status (7)

Country Link
US (2) US6630447B2 (fr)
EP (1) EP1263778B1 (fr)
AT (1) ATE294188T1 (fr)
AU (1) AU777721B2 (fr)
CA (1) CA2397485A1 (fr)
DE (1) DE60110396T2 (fr)
WO (1) WO2001051508A1 (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6844315B2 (en) 1998-05-20 2005-01-18 Erasmus Universiteit Rotterdam Immunoregulator
US20030220258A1 (en) 2001-12-21 2003-11-27 Robbert Benner Treatment of ischemic events
EP1138692A1 (fr) 2000-03-29 2001-10-04 Erasmus Universiteit Rotterdam Fragments de gonadotrophine chorionique humaine comme immunorégulateurs
US8680059B2 (en) 1998-05-20 2014-03-25 Biotempt B.V. Oligopeptide acetate and formulations thereof
USRE43279E1 (en) 2000-03-29 2012-03-27 Biotemp B.V. Compositions capable of reducing elevated blood urea concentration
US7358330B2 (en) 2001-03-29 2008-04-15 Biotempt B.V. Immunoregulatory compositions
US7786084B2 (en) 2001-12-21 2010-08-31 Biotempt B.V. Treatment of burns
WO2004032861A2 (fr) 2002-10-11 2004-04-22 Bristol-Myers Squibb Company Composes hexahydro-benzimidazolones utiles en tant qu'agents anti-inflammatoires
US20050048579A1 (en) * 2003-07-07 2005-03-03 Larson Richard S. Tertiary structures of ICAM-1/LFA-1 modulators
US20050119186A1 (en) * 2003-07-22 2005-06-02 Larson Richard S. Potent peptide inhibitors and methods of use
EP1682537B1 (fr) 2003-11-05 2012-03-28 SARcode Bioscience Inc. Modulateurs de l'adhesion cellulaire
TW200616634A (en) 2004-10-01 2006-06-01 Bristol Myers Squibb Co Crystalline forms and process for preparing spiro-hydantoin compounds
US7186727B2 (en) 2004-12-14 2007-03-06 Bristol-Myers Squibb Company Pyridyl-substituted spiro-hydantoin compounds and use thereof
ES2614080T3 (es) 2005-05-17 2017-05-29 Sarcode Bioscience Inc. Composiciones y métodos para el tratamiento de trastornos oculares
WO2007004869A2 (fr) 2005-07-05 2007-01-11 Biotempt B.V. Traitement de tumeurs
EP1864692A1 (fr) * 2006-06-07 2007-12-12 Biotempt B.V. Utilisation de peptides pour la protection contre les radiolésions
EP3797775A1 (fr) 2007-10-19 2021-03-31 Novartis AG Compositions et procédés pour le traitement de la rétinopathie diabétique
CN102056485A (zh) 2008-04-15 2011-05-11 萨可德公司 用于局部治疗免疫相关疾病的局部lfa-1拮抗剂
US8623322B2 (en) 2008-06-13 2014-01-07 Stc.Unm Non-invasive diagnostic agents and methods of diagnosing infectious disease
WO2020163876A1 (fr) * 2019-02-08 2020-08-13 The Regents Of The University Of California Compositions et méthodes impliquant la layiline

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9613112D0 (en) * 1996-06-21 1996-08-28 Zeneca Ltd Chemical compounds

Also Published As

Publication number Publication date
US6630447B2 (en) 2003-10-07
US20050065070A1 (en) 2005-03-24
AU2950201A (en) 2001-07-24
DE60110396T2 (de) 2006-01-19
EP1263778A1 (fr) 2002-12-11
CA2397485A1 (fr) 2001-07-19
WO2001051508A1 (fr) 2001-07-19
DE60110396D1 (de) 2005-06-02
US20010034326A1 (en) 2001-10-25
ATE294188T1 (de) 2005-05-15
AU777721B2 (en) 2004-10-28

Similar Documents

Publication Publication Date Title
EP1263778B1 (fr) Peptides inhibiteurs de l'interaction lfa-1/icam-1
US6649592B1 (en) Peptide inhibitors of LFA-1/ICAM-1 interaction
US6169071B1 (en) Compounds and methods for modulating cell adhesion
CA2129637C (fr) Traitement des affections intestinales inflammatoires
US20020151475A1 (en) Compounds and methods for modulating cell adhesion
WO1994020142A1 (fr) Dosages et methodes therapeutiques bases sur des facteurs de chimiotactisme
KR20000022075A (ko) 세포 접착 억제 화합물
US20200078442A1 (en) DPEP-1 Binding Compositions and Methods of Use
US20150297693A1 (en) Peptide inhibitors for mediating stress responses
AU2001268133C1 (en) Alpha-fetoprotein peptides and uses thereof
WO2006041205A1 (fr) Promoteur d'angiogenese
US6818741B2 (en) Alpha-fetoprotein peptides and uses therof
US6610821B1 (en) Compounds and methods for modulating endothelial cell adhesion
AU2001268133A1 (en) Alpha-fetoprotein peptides and uses thereof
JP2024028553A (ja) Ｄｐｅｐ－１結合剤および使用の方法
US6207639B1 (en) Compounds and methods for modulating neurite outgrowth
US6333307B1 (en) Compounds and method for modulating neurite outgrowth
US20060063701A1 (en) Methods and compositions for modulating C5-a-mediated inflammatory responses
US6107273A (en) Tumor necrosis factor inhibitors
US20050119186A1 (en) Potent peptide inhibitors and methods of use
Houimel et al. Random phage-epitope library based identification of a peptide antagonist of Mac-1 β2 integrin ligand binding
JP2004536041A (ja) 白血球インテグリンの新規ペプチドリガンド
Welzenbach Differential effects of low molecular weight inhibitors on the conformation and the immunologic function of the adhesion receptor LFA-1

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20020705

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

17Q First examination report despatched

Effective date: 20040223

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: LARSON, RICHARD S.

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT;WARNING: LAPSES OF ITALIAN PATENTS WITH EFFECTIVE DATE BEFORE 2007 MAY HAVE OCCURRED AT ANY TIME BEFORE 2007. THE CORRECT EFFECTIVE DATE MAY BE DIFFERENT FROM THE ONE RECORDED.

Effective date: 20050427

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20050427

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20050427

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20050427

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REF Corresponds to:

Ref document number: 60110396

Country of ref document: DE

Date of ref document: 20050602

Kind code of ref document: P

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20050727

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20050727

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20050727

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: TROESCH SCHEIDEGGER WERNER AG

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20050807

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20051010

NLV1 Nl: lapsed or annulled due to failure to fulfill the requirements of art. 29p and 29m of the patents act
PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20060110

Year of fee payment: 6

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20060111

Year of fee payment: 6

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20060112

Year of fee payment: 6

Ref country code: IE

Payment date: 20060112

Year of fee payment: 6

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20060113

Year of fee payment: 6

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20060131

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20060131

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 20060307

Year of fee payment: 6

ET Fr: translation filed
26N No opposition filed

Effective date: 20060130

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20070116

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20070131

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20070131

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20070801

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20070116

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

Effective date: 20070930

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20070116

BERE Be: lapsed

Owner name: *LARSON RICHARD S.

Effective date: 20070131

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20070131

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20070131

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20050427

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20050427